KICKSTART

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, April 4, 2024
Fulvestrant, KICKSTART, Survival, NSCLC, AML, Patient, Acute myeloid leukemia, Cancer, Hope, Pembrolizumab, Lung cancer, Therapy, Breast cancer, Safety, Cox, PFS, Interval (mathematics), Effector, Pharmaceutical industry

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.

Key Points: 
  • The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.
  • The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively.
  • There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.
  • “We sincerely appreciate the contributions of all the patients, their families, and trial site professionals who contributed to the execution of the trial.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

Retrieved on: 
Tuesday, January 9, 2024
KICKSTART, Winship Cancer Institute, Patient, Therapy, Hematology, Cancer, Q&A, NSCLC, ZFA, Pembrolizumab, Effector, Oncology, Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.

Key Points: 
  • -  Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET-
    SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
  • The eFFECTOR Investor R&D Day will feature the management team and include a presentation by Kevin Kalinsky, MD, MS, professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Glenn Family Breast Center at the Winship Cancer Institute.
  • Steve Worland, Ph.D., president and chief executive officer of eFFECTOR said: “We are pleased with the development progress of both of our wholly-owned Phase 2 drug candidates.
  • We look forward to showcasing both of our tomivosertib and zotatifin programs at our Investor R&D Day and are excited to have Dr. Kalinsky share his insights.”
    The presentations will be followed by a live Q&A session.

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Assistant, PD-L1, Associate, Therapy, Safety, D, RECIST, Fulvestrant, Effector, Expense, Investment, STRI Group, Artificial intelligence, Clinical trial, Breast cancer, Administration, D&O, Patient, PFS, Research, Science, Pembrolizumab, FA, KICKSTART, G&A, Messenger, ZFA, COVID-19, Hematology, Progression-free survival, ZF, Cancer, Death, R, AML, Research and development, MNK, Rated R, Cell, Society, Azacitidine, Pharmaceutical industry, Vaccine, Cryptocurrency, Genetics, Northwestern University, Medicine, NSCLC

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • These results, if positive, would enable activities, including interactions with regulatory agencies, intended to support initiation of a Phase 3 registrational trial.
  • Research and Development (R&D) Expenses: R&D expenses were $5.4 million for the quarter ended September 30, 2023, compared to $6.6 million for the same quarter of 2022.
  • Other Income (Expense): Other expense was $0.4 million for the quarter ended September 30, 2023, compared to $0.3 million for the same quarter of 2022.

eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Insurance, ER, Fulvestrant, G&A, MNK, Salk Institute for Biological Studies, Science, Patent, Patient, Investment, Artificial intelligence, Research and development, R, Therapy, Executive director, University, Champaign–Urbana metropolitan area, Research, Effector, Lung cancer, ZF, Drug discovery, ZFA, PD-L1, PR, Safety, D&O, Aes, Cancer, STRI Group, Messenger, PFS, Cell, Assistant, Expense, AbbVie, Administration, Pembrolizumab, Research fellow, Sale, ASCO, KICKSTART, Stanford University School of Medicine, FA, Breast cancer, Vaccine, Pharmaceutical industry, Cryptocurrency, Biochemistry, Genetics, NSCLC, Biology, Medicine

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • “It was another productive quarter for eFFECTOR as we made considerable progress on all fronts,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Topline data are anticipated in the second half of 2023.
  • $16.2 million in gross proceeds raised from two registered direct financings, extending cash runway into second quarter of 2024. eFFECTOR completed two registered direct financings during the second quarter of 2023.
  • eFFECTOR anticipates that its current cash, cash equivalents and short-term investments will be sufficient to fund operations into the second quarter of 2024.

eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Abstract, PRS, Metastatic breast cancer, American Society of Clinical Oncology, Cancer, Fulvestrant, STRI Group, G&A, Net operating loss, MNK, NSCLC, Effector, Lung cancer, Messenger, Cell, Assistant, Science, ASCO, QW, Expense, Patient, Investment, Administration, KICKSTART, Stanford University School of Medicine, Artificial intelligence, Research and development, R, Research, Pembrolizumab, Therapy, Safety, PD-L1, Society, ER, Breast cancer, Pharmaceutical industry, Vaccine, Cryptocurrency, Medicine, Genetics

SOLANA BEACH and REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Clinical data for zotatifin-based combination regimens in ER+ breast cancer have been selected for presentation at ASCO Annual Meeting 2023.
  • Management also intends to host a conference call to discuss results and further development of zotatifin during ASCO 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended March 31, 2023, compared to $3.1 million for the same quarter of 2022.
  • Other expense in the quarter ended March 31, 2023 consisted primarily of interest expense associated with the company’s term loans.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 8, 2023
Research and development, Effector, Cell, STRI Group, QW, Investment, NSCLC, University of California, San Francisco, KICKSTART, Pembrolizumab, MNK, ER, Lung cancer, DARPA, Therapy, PD-L1, Safety, Administration, San Francisco, Fulvestrant, R, COVID-19, University, Clinical trial, Expense, Cancer, CBR, Research, Net operating loss, Patient, PRS, G&A, Messenger, ORR, Cryptocurrency, Pharmaceutical industry, Vaccine, COVID

SOLANA BEACH and REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Revenue: Revenue was $0.7 million for the quarter ended December 31, 2022, compared to approximately $0.3 million for the same quarter of 2021.
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended December 31, 2022, compared to $6.4 million for the same quarter of 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $2.7 million for the quarter ended December 31, 2022, compared to $6.3 million for the same quarter of 2021.
  • Other Income (Expense): Other expense was $0.5 million for the quarter ended December 31, 2022 and other income for the quarter ended December 31, 2021 was $31.5 million.

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Retrieved on: 
Thursday, January 5, 2023
Lung cancer, Cancer, PRS, Clinical trial, Software, Pembrolizumab, Therapy, KRAS, Fulvestrant, COVID-19, CBR, ORR, Cyclin D1, Patient, Severe acute respiratory syndrome coronavirus 2, Attention, Safety, Maintenance, Webcast, Large-cell lung carcinoma, Effector, NSCLC, Stri Parva, KICKSTART, COVID, Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today provided an update on its ongoing clinical development programs for both zotatifin, in Phase 2 expansion cohorts for the treatment of estrogen receptor positive breast cancer (ER+ BC) and KRAS non-small cell lung cancer (KRAS NSCLC) as well as Phase 1 development for SARS-CoV-2 (COVID-19), and tomivosertib, in a Phase 2b trial for the treatment of non-small cell lung cancer (NSCLC) in combination with pembrolizumab, an established anti-immune checkpoint inhibitor used to treat various types of cancer.

Key Points: 
  • “With zotatifin, we continue to see activity across both ER+ BC expansion cohorts, and the drug continues to be generally well-tolerated.
  • The safety results to date have led us to believe that we may be able to increase the dose of zotatifin, which may achieve greater anti-tumor activity.
  • Therefore, we have resumed dose escalation and plan to wait for dose escalation data as well as data from the ongoing ECBF+A cohort before pursuing additional expansion cohorts.
  • ORR and CBR data for the remaining 11 patients is anticipated to be available in the first half of 2023.

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 7, 2022
Private Securities Litigation Reform Act, RNA transfection, Research and development, University of California, San Francisco, Infection, DARPA, University, D&O, Effector, Protein, U.S. Securities and Exchange Commission, COVID-19, IPO, Cyclin D1, Case Western Reserve University, Survival, Cyclic permutation, G&A, MNK, Pfizer, Genentech, PD-L1, 4F, San Francisco, GLOBE, NASDAQ, KRAS, Fulvestrant, Mayank Gandhi, Clinical trial, Administration, Research, Net operating loss, Therapy, R, Safety, Pembrolizumab, STRI, Patient, Expense, Cancer, CBO, Citigroup, Breast cancer, CMO, ER, Investment, Escape Room, Stri Parva, HIV disease progression rates, Security (finance), Medical imaging, Pharmaceutical industry, Management, Vaccine, Income, KICKSTART, NSCLC

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended September 30, 2022, compared to $5.0 million for the same quarter of 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.5 million for the quarter ended September 30, 2022, compared to $4.1 million for the same quarter of 2021.
  • Other Income (Expense): Other expense was $0.3 million for the quarter ended September 30, 2022 and other income for the quarter ended September 30, 2021 was $17.6 million.
  • Other expense in the quarter ended September 30, 2022 consisted primarily of interest expense associated with the companys term loan.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Escape Room, RNA transfection, EIF4E, Therapy, Survival, Stri, MNK, Pfizer, Pembrolizumab, KRAS, Cancer, 4F, GLOBE, STRI, COVID-19, University of California, San Francisco, ER, University, NASDAQ, Investor, Protein, Patient, San Francisco, SAN, DARPA, NSCLC, EIF4A, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.